Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors
PLOS One · 2025
DOI: 10.1371/journal.pone.0334632 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xiaofei Qin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, the First Affiliated Hospital of Xinxiang Medical University, Weihui, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Drug Design, Histone Deacetylase 1, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Histone deacetylases (HDACs) mediate the removal of acetyl groups from lysine residues in both histone and non-histone proteins, and have been regarded as promising targets for drug discovery. As a central member of HDAC family, HDAC1 has been found to be closely linked to the occurrence and development of prostate cancer. In this study, we designed and synthesized a new series of 3-phenylisoxazole HDAC1 inhibitors based on the hit 7 , identified by in-house compound library screening. The structure-activity relationship studies (SARs) indicated that the R 1 position was relatively tolerated for activity. The linker length at R 2 exerted a significant influence on activity with the relative orders of butyl > propyl > ethyl > methyl. Among synthetic 16 compounds, compound 17 indicated the strongest HDAC1 inhibitory effect with the inhibition rate of 86.78% at the concentration of 1000 nM. In addition, derivative 17 could not only well occupy the active pocket of HDAC1, but also showed favorable drug-like properties. More importantly, molecule 17 exerted potent anti-proliferative activity on prostate cancer PC3 cells with the IC 50 value of 5.82 μM, and had no significant toxicity against normal prostate WPMY-1 cells. Collectively, these findings validate phenylisoxazole derivative 17 as a promising lead compound for further optimization and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, the First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
- Clinical Pharmacy, Henan Province Key Subjects of Medicine, the First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
- Xinxiang Key Laboratory for Individualized Drug Use Research for Immune Diseases, Weihui, China.
- Xinxiang Anti-Oesophageal Cancer Nano-targeted Drug Delivery Engineering and Technology Research Centre, the First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
- Clinical Pharmacy, Xinxiang City Key Subjects of Medicine, the First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
ORCID-Profile: Xiaofei Qin
Zitieren
APA
Qin, X., Han, M., Hu, P., Que, H., Shao, Z., & Yan, D. (2025). Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors. PLOS One. https://doi.org/10.1371/journal.pone.0334632
Vancouver
Qin X, Han M, Hu P, Que H, Shao Z, Yan D. Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors. PLOS One. 2025. doi:10.1371/journal.pone.0334632
BibTeX
@article{Qin2025,
author = {Qin, Xiaofei and Han, Meng and Hu, Peng and Que, Huadong and Shao, Zhenlei and Yan, Dong},
title = {Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334632}
}
EUVIMED